Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation

Treatment of ALK-rearranged non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs) is challenged by the almost inevitable emergence of therapeutic resistance. Different profiles of resistance mechanisms have been reported for the currently available ALK TKIs. The ALK C1156Y mutati...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Chuangzhou Rao, Liangqin Nie, Xiaokang Wu, Xiaobo Miao, Ting Chen, Liuxi Chen, Dongqing Zhang, Quan Lin
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-09-01
coleção:	Frontiers in Oncology
Assuntos:	non-small cell lung cancer ALK C1156 crizotinib alectinib acquired resistance
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2022.915502/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!